- Lobbying
- Lobbying by Novartis Pharmaceuticals Pty Ltd ( Australia)
Lobbying Relationship
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist | Covered positions? |
---|---|
Nick Campbell Mr | n/a |
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
Termination
Q1 Report
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Trade (Domestic & Foreign)
Health Issues
Pharmacy
Q4 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Trade (Domestic & Foreign)
Health Issues
Pharmacy
Amendment
Lobbying Issues
Agencies Lobbied
Type of Issue
Trade (Domestic & Foreign)
Health Issues
Pharmacy
Q3 Report
Lobbying Issues
Agencies Lobbied
Type of Issue
Trade (Domestic & Foreign)
Health Issues
Pharmacy
Registration
Issue(s) they said they’d lobby about: Privileged & Confidential
The Australian Government's policy of initiating court proceedings to recovered damages from innovative pharmaceutical companies in cases where patents covering pharmaceutical benefits scheme (PBS)- listed medicines have been found invalid following an initial grant of an interlocutory injunction which delayed the launch of generic products.
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate